País: Irlanda
Idioma: inglés
Fuente: HPRA (Health Products Regulatory Authority)
EZETIMIBE, SIMVASTATIN
Actavis Group hf
C10BA02
EZETIMIBE, SIMVASTATIN
10/20 Milligram
Tablets
Product subject to prescription which may be renewed (B)
HMG CoA reductase inhibitors in combination with other lipid modifying agents
Authorised
2016-12-16
38 PACKAGE LEAFLET: INFORMATION FOR THE USER /…/ 10 MG/10 MG TABLETS /…/ 10 MG/20 MG TABLETS /…/ 10 MG/40 MG TABLETS /…/ 10 MG/80 MG TABLETS Ezetimibe/simvastatin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What /…/ is and what it is used for 2. What you need to know before you take /…/ 3. How to take /…/ 4. Possible side effects 5. How to store /…/ 6. Contents of the pack and other information 1. WHAT /…/ IS AND WHAT IT IS USED FOR /…/ is a medicine used to lower levels of total cholesterol, “bad” cholesterol (LDL cholesterol), and fatty substances called triglycerides in the blood. In addition, /…/ raises levels of “good” cholesterol (HDL cholesterol). /…/ works to reduce your cholesterol in two ways. The active ingredient ezetimibe reduces the cholesterol absorbed in your digestive tract. The active ingredient simvastatin belonging to the class of “statins” inhibits the production of the cholesterol your body makes by itself. Cholesterol is one of several fatty substances found in the bloodstream. Your total cholesterol is made up mainly of LDL and HDL cholesterol. LDL cholesterol is often called “bad” cholesterol because it can build up in the walls of your arteries forming plaque. Eventually this plaque bui Leer el documento completo
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ezetimibe/Simvastatin Actavis 10 mg/20 mg Tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg ezetimibe and 20 mg simvastatin. Excipient with known effect: Each 10 mg/20 mg tablet contains 112.45 mg of lactose monohydrate For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Ezetimibe/Simvastatin Actavis 10 mg/20 mg tablets: Light tan, mottled, round, 8 mm in diameter, biconvex tablets, plain on one side and “512” on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hypercholesterolaemia Ezetimibe/Simvastatin Actavis is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe Ezetimibe/Simvastatin Actavis contains ezetimibe and simvastatin. Simvastatin (20-40 mg) has been shown to reduce the frequency of cardiovascular events (see section 5.1). A beneficial effect of ezetimibe on cardiovascular morbidity and mortality has not yet been demonstrated. Homozygous Familial Hypercholesterolaemia (HoFH) Ezetimibe/Simvastatin Actavis is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g., low-density lipoprotein [LDL] apheresis). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Hypercholesterolaemia The patient should be on an appropriate lipid-lowering diet and should continue on this diet during treatment with Ezetimibe/Simvastatin Actavis. Route of administration is oral. The dosage range of Ezetimibe/Simvastatin Actavis is 10 mg/10 mg/day throug Leer el documento completo